Analysis of perturbed (test) and non-perturbed (control) human samples

  • Research type

    Research Study

  • Full title

    Physiological, biochemical and molecular analyses of primary somatic human stem and progenitor cells in response to chemicals, pharmacological agents or genetic perturbation for research and development purposes in Cellular Operations, a division of the Wellcome Sanger Institute.

  • IRAS ID

    283472

  • Contact name

    Andrew Bassett

  • Contact email

    ab42@sanger.ac.uk

  • Sponsor organisation

    The Wellcome Sanger Institute

  • Duration of Study in the UK

    6 years, 4 months, 9 days

  • Research summary

    Summary of Research
    The Division of Cellular Operations is a group of core scientists which serve to facilitate and optimise the Sanger Institute’s Faculty programmes of research. A large part of the Cellular Operations remit is developing and optimising tissue/cell culture assays including gene targeting and large scale screening. Improving efficiency of standard assays and development of novel scientific approaches, as a group, we are a core hub of expertise and extremely active in delivering Faculty science. Modern tissue culture techniques have been able to establish and improve the long term culture of primary human cells and tissues including the in vivo expansion of rare somatic stem and progenitor cell populations. These methods are under continuous development by the global scientific community. Importantly, any biological or scientific discoveries determined through the use of primary tissues, provide a more clinically tractable source of data than standard cell lines and represent an accompaniment to data from model organisms.

    We aim to study the effects of chemical, pharmacological or genetic perturbation and variation on the physiological, biochemical and molecular characteristics of somatic human primary stem (non-embryonic), progenitor (developing) and terminally differentiated (fully developed) cells from commercial suppliers or NHS Blood and Transplant (NHSBT). In particular we aim to drive the development of existing protocols with an aim to improving assay efficiencies, cost efficiencies and maximise the scientific return on these valuable resources. For all of the proposed studies genetically identical (isogenic), non-perturbed (control) samples will be assayed alongside perturbed (test) samples for direct comparison and protocol development. Briefly the studies will be comprised of two parts;

    i) optimisation and standardisation of techniques and conditions in non-perturbed samples.

    ii) comparison of perturbed (test) and non-perturbed matched (control) samples.

    Summary of Results
    n/a (study not started)

  • REC name

    North of Scotland Research Ethics Committee 2

  • REC reference

    20/NS/0079

  • Date of REC Opinion

    25 Jun 2020

  • REC opinion

    Favourable Opinion